Adrenal Cushing's Syndrome After Three Fractures: Adrenalectomy or Medical Management First
A single patient whose curable adrenal adenoma sits behind a real, recent fracture history that makes the cure itself dangerous, testing whether treating the hormone excess first can change that calculation.
Concetta R., a 78-year-old retired seamstress, broke her hip in a fall four months ago that, looking back, was the second of three fractures in under two years — a wrist the year before, and now two vertebral compression fractures found incidentally on the trauma CT that nobody had connected to anything until her hip surgeon, unsatisfied with "just osteoporosis" in someone otherwise active enough to still climb her own porch steps, ordered a cortisol workup. She still does her own grocery shopping and had, until the hip fracture, resisted every suggestion of a walker, a detail her daughter mentions with visible pride and visible worry in the same breath. A 1 mg overnight dexamethasone suppression test came back at 9.4 mcg/dL, ACTH was suppressed below assay detection, and a 2.8 cm left adrenal adenoma on CT completed the picture: adrenal Cushing's syndrome, almost certainly the real driver of bone loss that had been quietly reframed as ordinary aging for years. Laparoscopic adrenalectomy is curative for a unilateral cortisol-producing adenoma of this size, and in a healthier patient would not be a hard decision. She is recovering from a hip fracture repair four months ago, has vertebral compression fractures adding real limitation to positioning and mobility, and her hip surgeon's own anesthesia consult flagged fall-and-fracture history alongside age as compounding surgical risk factors independent of anything cardiac.
The question the team actually disagrees about is not whether adrenalectomy would cure her — it would — but whether curing the hypercortisolism first, medically, might itself lower her surgical risk by slowing the same bone loss and frailty trajectory that make surgery risky in the first place, or whether that reasoning simply delays a cure she may tolerate now better than she will in another year.
Endocrine surgery and geriatrics, joint consultation
Her cardiac and renal workup is reassuring, and a 2.8 cm unilateral adenoma is exactly the tumor laparoscopic adrenalectomy handles well. I'm concerned that every month we wait is a month of active cortisol excess doing more to her bones — she's already had three fractures. Delay doesn't protect her from surgical risk, it plausibly manufactures more of it.
Three fractures in two years, the most recent one four months ago, with vertebral compression fractures still limiting her positioning tolerance — that's not a background risk factor to note and move past, it's the central fact of her surgical candidacy. Medical management of hypercortisolism in poor surgical candidates is an established, not experimental, path — the 2021 Pituitary Society consensus (Fleseriu et al.) treats chronic steroidogenesis inhibition as a legitimate primary strategy, not only a surgical bridge, in patients for whom an operation carries disproportionate risk.
Ask it the other way round: what would have to be true about her hips and her spine before you would call this operation low-risk? Because whatever that answer is, four months out from a hip repair with two compression fractures still limiting how she can be positioned, she is not it yet.
I don't think we have to decide today whether medical management is temporary or permanent for her. Start ketoconazole rather than metyrapone or osilodrostat — the 11-beta-hydroxylase inhibitors drive up mineralocorticoid precursors and can worsen the hypertension and hypokalemia she does not need on top of everything else — with liver function checked at baseline, two weeks, then monthly, since hepatotoxicity is the real cost of that choice. Recheck bone turnover markers and her functional mobility at three months. If cortisol control measurably improves her fracture risk and mobility, that's real information about whether surgery later carries less risk than surgery today — and if it doesn't move, we haven't lost meaningful ground, since her adenoma isn't growing on this timeline.
Agreed: a three-month trial of ketoconazole with reassessment of bone turnover markers and functional mobility, deferring the surgical decision rather than committing to either path today.
Not agreed: how much improvement should count as enough to justify surgery afterward versus continuing medical management indefinitely. The surgeon views any meaningful mobility improvement as grounds to proceed, given the tumor is still there and still curable; the geriatrician would want a higher bar given how recent and how severe her fracture history already is, and is open to indefinite medical management if that bar isn't clearly met.